Table 1 Demographic and clinical characteristics of the patients included in this study, classified by their ICU stay outcome 18.
ICU non-survival (n = 38) | ICU survival (n = 16) | Non-ICU symptomatic (n = 16) | ρ between non-survival and survival groups | |
---|---|---|---|---|
Demographic characteristics | ||||
Female % | 31.58 | 25 | 25 | nsa |
Age in years (Mean ± SD) | 71 ± 9.87 | 64 ± 10.15 | 70 ± 14.25 | 0.023b |
Sample per patient | 1.87 ± 0.93 | 1.94 ± 0.93 | 1 | nsc |
Clinical characteristics | ||||
PaO2/FiO2 at ICU admission (Median, p25-p75) | 93 (83.5–109.8) | 159.5 (128–191.8) | – | < 0.0001c |
SOFA score at admission (Median, p25-p75) | 7 (6–9) | 4.5 (3.25–5) | – | < 0.0001c |
APACHE II score at admission (Median, p25-p75) | 16 (15–22) | 10.5 (8.25–13) | – | < 0.0001c |
SARS-CoV-2 Immunization started (%) | 0 | 0 | 6.25 | nsa |
Comorbidities | ||||
Coronary heart disease (%) | 23.68 | 12.5 | 18.75 | nsa |
Hypertension (%) | 76.32 | 68.75 | 62.5 | nsa |
Diabetes (%) | 39.47 | 18.75 | 25 | nsa |
Obesity (%) | 26.32 | 43.75 | 12.5 | nsa |
Cancer (%) | 5.26 | 12.5 | 12.5 | nsa |
Chronic respiratory disease (%) | 15.79 | 18.75 | 6.25 | nsa |
Immunosuppression (%) | 2.63 | 0 | 0 | nsa |
Number of comorbidities (Median, p25-p75) | 2 (1–3) | 2 (1–2.75) | 1 (0–2.75) | nsc |